ArticlePloS one2026
Does receiving red yeast rice prescriptions (LipoCol Forte®) increase the risk of end-stage renal disease or not? A retrospective cohort study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe potential relationship between the consumption of red yeast rice (RYR) and the development of end-stage renal disease (ESRD) remains poorly understood. We aimed to evaluate the risk of ESRD in patients who used RYR.
methodsUtilizing insurance claim records from 2010 to 2014, we performed a retrospective cohort analysis comparing 67,876 individuals using RYR against a control group of 90,836 lovastatin users (non-RYR group), with follow-up extending through 2019. The incidence of ESRD was analyzed using adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) within Cox proportional hazard models.
resultsDuring follow-up, the ESRD incidence was 0.9 per 1,000 person-years in RYR users, compared to 3.7 per 1,000 person-years in lovastatin users (HR 0.36, 95% CI 0.32-0.40). A dose-dependent reduction in ESRD risk was observed with increasing RYR prescriptions. Sensitivity analysis, excluding ESRD cases within the initial six months, confirmed a persistent association between RYR use and reduced ESRD risk (adjusted HR 0.72, 95% CI 0.64-0.81).
conclusionRYR intake may be linked to a decreased likelihood of progressing to ESRD. Despite these promising results, factors such as medication adherence necessitate cautious interpretation. Further randomized controlled trials are required to validate these findings and clarify RYR's role in slowing kidney disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.